Researchers from KAUST, King Faisal Specialist Hospital, and collaborators have developed a new method to predict cardiometabolic disease risk in underrepresented ethnic populations using genetic information and public databases. The study focused on Arab communities and created a framework to determine polygenic scores for more accurate heart disease prediction. The framework was validated using records of over 5,000 Arab patients, demonstrating that genetic risk complements conventional risk factors. Why it matters: This research addresses a critical gap in genomic data for non-European populations, potentially leading to more effective and personalized healthcare strategies in the Arab world and beyond.
KAUST researchers, in collaboration with the Salk Institute and Altos Labs, have identified a class of RNA (LINE-1) that, when compromised, leads to accelerated aging, as seen in progeria. They devised an antisense RNA strategy to block the aberrant function of L1 RNA, reversing the disease in mice and patient-derived cells. Published in Science Translational Medicine, the research suggests that targeting LINE-1 RNA could treat progeroid syndromes and other age-related diseases. Why it matters: This RNA-based approach provides a potential therapeutic avenue for treating premature aging diseases and extending human health span in the region and globally.
KAUST and the Saudi Food and Drug Authority (SFDA) have partnered to develop a new method using nuclear magnetic resonance (NMR) to detect adulterants in olive oil. The method aims to identify and quantify vegetable oils mixed with olive oil, addressing concerns about the mislabeling of olive oil in the Saudi market. KAUST's comprehensive suite of NMR machines was critical for the project. Why it matters: This collaboration enhances food safety and quality control in Saudi Arabia, a major olive oil importer, and helps to ensure consumers receive authentic, high-quality products.
KAUST researchers developed a statistical approach to improve the identification of cancer-related protein mutations by reducing false positives. The method uses Bayesian statistics to analyze protein domain data from tumor samples, accounting for potential errors due to limited data. The team tested their method on prostate cancer data, successfully identifying a known cancer-linked mutation in the DNA binding protein cd00083. Why it matters: This enhances the reliability of cancer research at the molecular level, potentially accelerating the discovery of new therapeutic targets.
KAUST researchers led by Dr. Niveen Khashab have developed thermosensitive liposomes for controlled drug release, particularly in cancer therapies. The liposomes are designed to release drugs only when they reach heated tumor tissue, minimizing systemic side effects. Cholesterol moieties are used as anchors to create a "nail" or "comb" effect, enabling temperature-triggered drug release inside cells. Why it matters: This targeted drug delivery system could significantly improve the efficacy and reduce the toxicity of cancer treatments.
ANSYS, Saudi Aramco, and KAUST have achieved a new supercomputing milestone, though specific details about the achievement are not provided in the content. The announcement references KAUST Discovery. The mention of King Abdullah suggests a connection to the university's founding. Why it matters: Such milestones could enhance research capabilities and innovation in the region, particularly in areas relevant to Saudi Aramco's interests.